Page last updated: 2024-11-13

talatisamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

talatisamine: diterpenoid alkaloids found in folk medicine caowu; RN given refers to ((1alpha,14alpha,16beta)-isomer); RN for cpd without isomeric designation not avail 8/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID102004486
MeSH IDM0190456

Synonyms (3)

Synonym
talatisamine
20501-56-8
AKOS037514853

Research Excerpts

Overview

Talatisamine is a novel I(K) channel blocker discovered by virtual screening and electrophysiological characterization.

ExcerptReferenceRelevance
"Talatisamine is a novel I(K) channel blocker discovered by virtual screening and electrophysiological characterization."( The newly identified K+ channel blocker talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons.
Chen, H; Hou, L; Song, M; Wang, Y; Yu, Z, 2012
)
1.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's4 (44.44)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.23 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]